STERIS (STE) Stock Forecast, Price Target & Predictions
STE Stock Forecast
STERIS stock forecast is as follows: an average price target of $245.00 (represents a 0.07% upside from STE’s last price of $244.83) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
STE Price Target
The average price target for STERIS (STE) is $245.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $265.00 to $225.00. This represents a potential 0.07% upside from STE's last price of $244.83.
STE Analyst Ratings
According to 5 Wall Street analysts, STERIS's rating consensus is 'Buy'. The analyst rating breakdown for STE stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
STERIS Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 03, 2024 | Brett Fishbin | KeyBanc | $265.00 | $241.10 | 9.91% | 8.24% |
| May 10, 2024 | Jason Bednar | Piper Sandler | $225.00 | $225.94 | -0.42% | -8.10% |
| Apr 04, 2024 | Mike Polark | Wolfe Research | $245.00 | $216.65 | 13.09% | 0.07% |
The latest STERIS stock forecast, released on Sep 03, 2024 by Brett Fishbin from KeyBanc, set a price target of $265.00, which represents a 9.91% increase from the stock price at the time of the forecast ($241.10), and a 8.24% increase from STE last price ($244.83).
STERIS Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 3 |
| Avg Price Target | $265.00 | $265.00 | $245.00 |
| Last Closing Price | $244.83 | $244.83 | $244.83 |
| Upside/Downside | 8.24% | 8.24% | 0.07% |
In the current month, the average price target of STERIS stock is $265.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 8.24% increase as opposed to STERIS's last price of $244.83. This month's average price target is down 0.00% compared to last quarter, and up 8.16% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | Stephens | Market Outperform | Market Outperform | Hold |
| Sep 03, 2024 | JMP Securities | Underperform | Underperform | Hold |
| Sep 03, 2024 | KeyBanc | Overweight | Overweight | Hold |
| Aug 07, 2024 | Stephens | Market Outperform | Market Outperform | Hold |
| Jun 10, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| May 10, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Apr 04, 2024 | Wolfe Research | Outperform | Outperform | Hold |
| Feb 09, 2024 | Stephens | Market Outperform | Market Outperform | Hold |
| Aug 03, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
STERIS's last stock rating was published by Stephens on Sep 03, 2024. The company gave STE a "Market Outperform" rating, the same as its previous rate.
STERIS Financial Forecast
STERIS Revenue Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.40B | $1.34B | $1.28B | $1.38B | $1.22B | $1.20B | $1.16B | $1.21B | $968.42M | $1.20B | $1.21B | $873.53M | $668.93M | $756.13M | $808.92M | $822.99M | $696.80M |
| Avg Forecast | $1.69B | $1.54B | $1.49B | $1.43B | $1.59B | $1.47B | $1.41B | $1.36B | $1.50B | $1.38B | $1.33B | $1.27B | $1.41B | $1.35B | $1.30B | $1.21B | $1.27B | $1.27B | $1.22B | $1.22B | $1.17B | $1.19B | $1.15B | $904.86M | $876.22M | $793.03M | $719.54M | $643.38M | $799.57M | $748.45M |
| High Forecast | $1.73B | $1.58B | $1.52B | $1.47B | $1.62B | $1.50B | $1.44B | $1.39B | $1.54B | $1.41B | $1.35B | $1.30B | $1.44B | $1.36B | $1.31B | $1.24B | $1.30B | $1.30B | $1.25B | $1.25B | $1.20B | $1.22B | $1.17B | $922.37M | $893.17M | $808.38M | $733.46M | $655.83M | $815.04M | $762.93M |
| Low Forecast | $1.68B | $1.53B | $1.47B | $1.42B | $1.57B | $1.46B | $1.40B | $1.34B | $1.49B | $1.37B | $1.31B | $1.26B | $1.40B | $1.34B | $1.28B | $1.20B | $1.26B | $1.26B | $1.21B | $1.21B | $1.16B | $1.18B | $1.14B | $892.78M | $864.52M | $782.45M | $709.94M | $634.80M | $788.90M | $738.46M |
| # Analysts | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.03% | 1.06% | 1.09% | 0.96% | 0.98% | 0.95% | 1.03% | 0.81% | 1.04% | 1.34% | 1.00% | 0.84% | 1.05% | 1.26% | 1.03% | 0.93% |
STERIS's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.41B, with a low forecast of $1.40B, and a high forecast of $1.44B. STE's average Quarter revenue forecast represents a 1.13% increase compared to the company's last Quarter revenue of $1.40B (Dec 23).
STERIS EBITDA Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $216.16M | $185.86M | $188.92M | $226.12M | $190.88M | $318.09M | $158.45M | $91.92M | $76.47M | $230.90M | $322.78M | $203.66M | $165.41M | $196.79M | $205.17M | $208.54M | $158.58M |
| Avg Forecast | $332.88M | $302.97M | $292.38M | $282.15M | $312.16M | $289.02M | $277.71M | $266.89M | $295.16M | $271.88M | $261.77M | $250.28M | $344.19M | $265.25M | $255.54M | $237.49M | $312.90M | $250.34M | $231.75M | $240.60M | $284.45M | $234.89M | $226.54M | $177.97M | $224.86M | $155.98M | $141.52M | $126.54M | $200.70M | $147.21M |
| High Forecast | $340.63M | $310.02M | $299.19M | $288.72M | $319.43M | $295.75M | $284.18M | $273.11M | $302.04M | $278.21M | $265.68M | $256.11M | $413.03M | $267.23M | $258.37M | $243.02M | $375.48M | $256.17M | $278.10M | $245.26M | $341.34M | $239.43M | $230.92M | $181.42M | $269.84M | $159.00M | $144.26M | $128.99M | $240.85M | $150.06M |
| Low Forecast | $329.80M | $300.17M | $289.68M | $279.54M | $309.28M | $286.35M | $275.14M | $264.43M | $292.44M | $269.36M | $257.86M | $247.97M | $275.35M | $263.27M | $252.28M | $235.29M | $250.32M | $248.03M | $185.40M | $237.39M | $227.56M | $231.75M | $223.51M | $175.60M | $179.89M | $153.90M | $139.63M | $124.86M | $160.56M | $145.24M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | 0.73% | 0.80% | 0.72% | 0.76% | 1.37% | 0.66% | 0.32% | 0.33% | 1.02% | 1.81% | 0.91% | 1.06% | 1.39% | 1.62% | 1.04% | 1.08% |
1 analysts predict STE's average Quarter EBITDA for Mar 24 to be $344.19M, with a high of $413.03M and a low of $275.35M. This is 59.23% upper than STERIS's previous annual EBITDA (Dec 23) of $216.16M.
STERIS Net Income Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $140.74M | $115.32M | $123.55M | $187.22M | $123.83M | $-315.23M | $111.26M | $52.26M | $-21.90M | $69.81M | $-21.81M | $88.85M | $88.12M | $105.86M | $88.19M | $123.32M | $104.93M |
| Avg Forecast | $322.68M | $280.07M | $261.69M | $244.10M | $285.54M | $252.75M | $235.52M | $227.90M | $263.20M | $232.26M | $212.10M | $196.48M | $147.46M | $215.50M | $199.08M | $184.84M | $134.05M | $217.96M | $70.08M | $190.31M | $121.87M | $194.98M | $180.86M | $148.27M | $96.34M | $150.89M | $125.88M | $97.19M | $118.63M | $141.11M |
| High Forecast | $332.45M | $288.55M | $269.61M | $251.49M | $294.19M | $260.40M | $242.65M | $234.80M | $271.17M | $239.29M | $218.10M | $202.43M | $176.95M | $217.50M | $205.03M | $190.44M | $160.87M | $224.56M | $84.09M | $195.09M | $146.24M | $199.88M | $185.41M | $152.00M | $115.61M | $154.68M | $129.04M | $99.63M | $142.36M | $144.66M |
| Low Forecast | $318.81M | $276.71M | $258.54M | $241.16M | $282.11M | $249.71M | $232.69M | $225.16M | $260.04M | $229.47M | $206.09M | $194.12M | $117.97M | $214.51M | $188.19M | $182.62M | $107.24M | $215.35M | $56.06M | $187.00M | $97.49M | $191.59M | $177.73M | $145.70M | $77.07M | $148.27M | $123.69M | $95.50M | $94.91M | $138.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.65% | 0.58% | 0.67% | 1.40% | 0.57% | -4.50% | 0.58% | 0.43% | -0.11% | 0.39% | -0.15% | 0.92% | 0.58% | 0.84% | 0.91% | 1.04% | 0.74% |
STERIS's average Quarter net income forecast for Mar 24 is $147.46M, with a range of $117.97M to $176.95M. STE's average Quarter net income forecast represents a 4.77% increase compared to the company's last Quarter net income of $140.74M (Dec 23).
STERIS SG&A Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $360.52M | $380.65M | $359.06M | $335.91M | $305.14M | $323.19M | $334.63M | $453.64M | $393.75M | $344.80M | $310.56M | $221.07M | $155.17M | $172.71M | $182.37M | $189.06M | $178.78M |
| Avg Forecast | $440.00M | $400.47M | $386.47M | $372.95M | $412.62M | $382.03M | $367.08M | $352.79M | $390.15M | $359.37M | $346.01M | $330.83M | $366.90M | $350.61M | $337.79M | $313.92M | $333.54M | $330.91M | $346.12M | $318.04M | $303.22M | $310.48M | $299.44M | $235.25M | $239.70M | $206.18M | $187.07M | $167.27M | $181.88M | $194.58M |
| High Forecast | $450.25M | $409.79M | $395.48M | $381.64M | $422.23M | $390.93M | $375.63M | $361.00M | $399.24M | $367.74M | $351.18M | $338.53M | $440.28M | $353.23M | $341.52M | $321.23M | $400.25M | $338.62M | $415.34M | $324.19M | $363.86M | $316.49M | $305.24M | $239.80M | $287.64M | $210.16M | $190.69M | $170.51M | $218.26M | $198.35M |
| Low Forecast | $435.94M | $396.77M | $382.90M | $369.50M | $408.81M | $378.50M | $363.69M | $349.53M | $386.55M | $356.05M | $340.85M | $327.77M | $293.52M | $347.99M | $333.46M | $311.02M | $266.83M | $327.85M | $276.89M | $313.79M | $242.58M | $306.33M | $295.45M | $232.11M | $191.76M | $203.42M | $184.57M | $165.04M | $145.51M | $191.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.13% | 1.14% | 1.01% | 0.92% | 0.93% | 1.05% | 1.50% | 1.27% | 1.15% | 1.32% | 0.92% | 0.75% | 0.92% | 1.09% | 1.04% | 0.92% |
STERIS's average Quarter SG&A projection for Mar 24 is $366.90M, based on 1 Wall Street analysts, with a range of $293.52M to $440.28M. The forecast indicates a 1.77% rise compared to STE last annual SG&A of $360.52M (Dec 23).
STERIS EPS Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.42 | $1.17 | $1.25 | $1.89 | $1.24 | $-3.15 | $1.11 | $0.52 | $-0.24 | $0.70 | $1.43 | $1.02 | $1.04 | $1.24 | $1.34 | $1.45 | $1.00 |
| Avg Forecast | $3.25 | $2.82 | $2.63 | $2.46 | $2.87 | $2.54 | $2.37 | $2.29 | $2.65 | $2.34 | $2.13 | $1.98 | $2.35 | $2.17 | $2.00 | $1.86 | $2.15 | $2.19 | $1.98 | $1.92 | $2.02 | $1.96 | $1.82 | $1.49 | $1.77 | $1.52 | $1.27 | $0.98 | $1.57 | $1.42 |
| High Forecast | $3.35 | $2.90 | $2.71 | $2.53 | $2.96 | $2.62 | $2.44 | $2.36 | $2.73 | $2.41 | $2.19 | $2.04 | $2.42 | $2.19 | $2.06 | $1.92 | $2.21 | $2.26 | $2.04 | $1.96 | $2.07 | $2.01 | $1.87 | $1.53 | $1.82 | $1.56 | $1.30 | $1.00 | $1.61 | $1.46 |
| Low Forecast | $3.21 | $2.78 | $2.60 | $2.43 | $2.84 | $2.51 | $2.34 | $2.27 | $2.62 | $2.31 | $2.07 | $1.95 | $2.32 | $2.16 | $1.89 | $1.84 | $2.12 | $2.17 | $1.96 | $1.88 | $1.99 | $1.93 | $1.79 | $1.47 | $1.74 | $1.49 | $1.24 | $0.96 | $1.55 | $1.40 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.65% | 0.58% | 0.67% | 0.88% | 0.57% | -1.59% | 0.58% | 0.26% | -0.12% | 0.38% | 0.96% | 0.57% | 0.68% | 0.98% | 1.37% | 0.92% | 0.70% |
According to 1 Wall Street analysts, STERIS's projected average Quarter EPS for Mar 24 is $2.35, with a low estimate of $2.32 and a high estimate of $2.42. This represents a 65.49% increase compared to STE previous annual EPS of $1.42 (Dec 23).
STERIS Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IRTC | iRhythm | $76.61 | $144.20 | 88.23% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| LIVN | LivaNova | $48.53 | $71.25 | 46.82% | Buy |
| MASI | Masimo | $112.80 | $158.40 | 40.43% | Buy |
| CNMD | CONMED | $75.40 | $101.00 | 33.95% | Buy |
| PEN | Penumbra | $186.94 | $218.89 | 17.09% | Hold |
| PODD | Insulet | $233.87 | $268.60 | 14.85% | Buy |
| BRKR | Bruker | $65.66 | $71.67 | 9.15% | Buy |
| ITGR | Integer | $126.78 | $131.00 | 3.33% | Buy |
| STE | STERIS | $244.83 | $245.00 | 0.07% | Buy |
| ZIMV | ZimVie | $16.45 | $14.50 | -11.85% | Buy |
| SYK | Stryker | $370.25 | $305.00 | -17.62% | Buy |
| GKOS | Glaukos | $126.28 | $101.56 | -19.58% | Buy |
STE Forecast FAQ
Is STERIS a good buy?
Yes, according to 5 Wall Street analysts, STERIS (STE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of STE's total ratings.
What is STE's price target?
STERIS (STE) average price target is $245 with a range of $225 to $265, implying a 0.07% from its last price of $244.83. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will STERIS stock go up soon?
According to Wall Street analysts' prediction for STE stock, the company can go up by 0.07% (from the last price of $244.83 to the average price target of $245), up by 8.24% based on the highest stock price target, and down by -8.10% based on the lowest stock price target.
Can STERIS stock reach $400?
STE's average twelve months analyst stock price target of $245 does not support the claim that STERIS can reach $400 in the near future.
What is STERIS's current price target trend?
1 Wall Street analyst forecast a $265 price target for STERIS (STE) this month, up 8.24% from its last price of $244.83. Compared to the last 3 and 12 months, the average price target increased by 8.24% and increased by 0.07%, respectively.
What are STERIS's analysts' financial forecasts?
STERIS's analysts financial forecasts for the fiscal year (Mar 2026) are as follows: average revenue is $5.83B (high $5.96B, low $5.77B), average EBITDA is $1.15B (high $1.17B, low $1.14B), average net income is $1B (high $1.03B, low $989.67M), average SG&A $1.51B (high $1.55B, low $1.5B), and average EPS is $10.08 (high $10.39, low $9.96). STE's analysts financial forecasts for the fiscal year (Mar 2027) are as follows: average revenue is $6.15B (high $6.3B, low $6.1B), average EBITDA is $1.21B (high $1.24B, low $1.2B), average net income is $1.11B (high $1.14B, low $1.1B), average SG&A $1.6B (high $1.64B, low $1.59B), and average EPS is $11.16 (high $11.49, low $11.02).
Did the STE's actual financial results beat the analysts' financial forecasts?
Based on STERIS's last annual report (Mar 2023), the company's revenue was $4.96B, which missed the average analysts forecast of $4.99B by -0.66%. Apple's EBITDA was $1.25B, beating the average prediction of $1.04B by 20.73%. The company's net income was $107.03M, missing the average estimation of $612.4M by -82.52%. Apple's SG&A was $1.3B, missing the average forecast of $1.33B by -2.24%. Lastly, the company's EPS was $1.07, missing the average prediction of $8.24 by -87.01%. In terms of the last quarterly report (Dec 2023), STERIS's revenue was $1.4B, beating the average analysts' forecast of $1.35B by 3.49%. The company's EBITDA was $216.16M, missing the average prediction of $265.25M by -18.51%. STERIS's net income was $140.74M, missing the average estimation of $215.5M by -34.69%. The company's SG&A was $360.52M, beating the average forecast of $350.61M by 2.83%. Lastly, the company's EPS was $1.42, missing the average prediction of $2.17 by -34.52%